Provectus Pharmaceuticals Inc Sample Contracts

AGREEMENT ---------
Registration Rights Agreement • November 5th, 2004 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • Tennessee
Agreement ---------
Consulting Agreement • October 1st, 2003 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • February 28th, 2013 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations

This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 22, 2013, between Provectus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

AGREEMENT ---------
Settlement Agreement • June 26th, 2003 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations
INDEMNIFICATION AGREEMENT
Indemnification Agreement • July 16th, 2020 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of July 20, 2020, between PROVECTUS Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Webster Bailey (“Indemnitee”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • August 25th, 2016 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of August 25, 2016, between Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • December 23rd, 2010 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • Nevada

REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of December 22, 2010, by and between PROVECTUS PHARMACEUTICALS, INC., a Nevada corporation, (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").

PROVECTUS BIOPHARMACEUTICALS, INC. Up to $50,000,000 of Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement
Provectus Biopharmaceuticals, Inc. • April 30th, 2014 • Pharmaceutical preparations • New York

Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:

Recitals
Consulting Agreement • September 17th, 2002 • Provectus Pharmaceuticals Inc • Special industry machinery, nec
PROVECTUS BIOPHARMACEUTICALS, INC. DEALER-MANAGER AGREEMENT January 30, 2017
Dealer-Manager Agreement • February 3rd, 2017 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York

The following (this “Agreement”) will confirm our agreement relating to the proposed rights offering (the “Rights Offering”) to be undertaken by Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to which the Company will distribute to holders of record of its common stock, par value $0.001 per share (the “Common Stock”), and holders of the Company’s class of warrants with an exercise price of $0.85 per share expiring June 19, 2020 (“Listed Warrants”) subscription rights (the “Rights”) to purchase up to an aggregate of 19,662,782 units (the “Units”), each Unit consisting of four shares of Common Stock (the “Rights Shares”) and one-half share of Series C Convertible Preferred Stock (the “Preferred Stock”), at a subscription price of $1.00 per Unit in cash (the “Subscription Price”). The Subscription Price is subject to decrease by up to 20% by the Company after consultation with the Dealer-Manager, as described in the Prospectus (as defined herein).

EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • March 13th, 2014 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • Tennessee

THIS AGREEMENT made as of this 1st day of July 2013 by and between PROVECTUS PHARMACEUTICALS, INC., a Nevada Corporation with its principal place of business in Knoxville, Tennessee (the “Company”), and Timothy C. Scott, Ph.D. (the “Executive”).

RECITALS
Reaffirmation Agreement • May 16th, 2005 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations
Contract
Securities Purchase Agreement • March 12th, 2010 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT
Warrant Agency Agreement • June 19th, 2015 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York

WARRANT AGENCY AGREEMENT made as of June , 2015 (“Issuance Date”), between Provectus Biopharmaceuticals, Inc., a Delaware corporation, with offices at 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931 (the “Company”), and Broadridge Corporate Issuer Solutions, Inc., with offices at 1717 Arch Street, Suite 1300, Philadelphia, Pennsylvania 19103 (the “Warrant Agent”).

August 25, 2016
Provectus Biopharmaceuticals, Inc. • August 25th, 2016 • Pharmaceutical preparations • New York
PURCHASE AGREEMENT
Purchase Agreement Purchase Agreement • July 26th, 2013 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New York

PURCHASE AGREEMENT (the “Agreement”), dated as of July 22, 2013, by and between PROVECTUS PHARMACEUTICALS, INC., a Nevada corporation, (the “Company”), and ALPHA CAPITAL ANSTALT (the “Investor”).